抗耐甲氧西林金黄色葡萄球菌的新型氟喹诺酮类药物德拉沙星  

A novel fluoroquinolone antibiotic for methicillin-resistant staphylococcus aureus:delafloxacin

作　　者：李双 王琳 杨君义 卢秀花 LI Shuang;WANG Lin;YANG Jun-yi;LU Xiu-hua(Department of Pharmacy;Department of Pain Management,Central Hospital of Linyi City,Linyi 276400,China)

机构地区：[1]临沂市中心医院药学部,临沂276400 [2]临沂市中心医院疼痛科,临沂276400

出　　处：《中国新药杂志》2018年第19期2227-2231,共5页Chinese Journal of New Drugs

摘　　要：德拉沙星(delafloxacin)是一种新型广谱氟喹诺酮类抗菌药物,作用靶点为DNA旋转酶和拓扑异构酶IV,抗菌谱覆盖革兰阳性球菌[包括耐甲氧西林金黄色葡萄球菌(methicillin-resistant staphylococcus aureus,MRSA)]、革兰阴性杆菌、厌氧菌及非典型病原体,2017年6月19日被美国FDA批准治疗急性细菌性皮肤和皮肤结构感染(acute bacterial skin and skin structure infections,ABSSSIS)。其耐受性好,不良反应较少,对患者QT间期及心率无影响,无明显的光毒性。Delafloxacin is a novel fluoroquinolone antibiotic with activity against gram-positive,gramnegative,anaerobic and atypical pathogens,including methicillin-resistant staphylococcus aureus（ MRSA）. It acts on two kinds of bacterial enzymes involved in the replication of genetic materials,DNA-gyrase and topoisomerase IV. The drug was approved by the FDA on June 19,2017 for the treatment of acute bacterial skin and skin structure infections（ ABSSSIS）. Delafloxacin has good tolerability and few adverse reactions,and it does not have clinically significant effects on QT interval or heart rate or phototoxicity.

关 键 词：德拉沙星 耐甲氧西林金黄色葡萄球菌 氟喹诺酮类药物 急性细菌性皮肤和皮肤结构感染 

分 类 号：R979.1[医药卫生—药品]